The methenamine hippurate tablets market size has grown strongly in recent years. It will grow from $10.11 billion in 2025 to $10.86 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to limited awareness about recurrent uti prevention, restricted access to specialized urology care, low adoption of antimicrobial tablets, reliance on hospital-based treatment, traditional packaging formats.
The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing incidence of urinary tract infections, growing demand for outpatient and homecare treatment, technological advancements in tablet formulation, rising adoption of personalized medicine, expansion of online pharmacy channels. Major trends in the forecast period include rising prevalence of recurrent utis, growth in geriatric population, increasing preference for oral antimicrobial therapies, expansion of home healthcare services, emergence of personalized medication regimens.
The rising incidence of urinary tract infections (UTIs) is expected to drive the growth of the methenamine hippurate tablets market. UTIs are common infections that occur when bacteria enter the urethra and infect the urinary tract, often originating from the skin or rectum. Methenamine hippurate tablets are used to prevent or treat recurrent UTIs caused by specific bacteria. For example, in October 2023, the National Health Service (NHS), a UK-based government department, reported that during the 2022-23 period, there were 147,285 hospital admissions for UTIs as the primary diagnosis. Of these, 56% (82,392) were individuals aged 65 and older, with the highest number of admissions occurring in the 80-84 age group, which accounted for 17,280 admissions. As a result, the rising number of UTI cases is contributing to the growth of the methenamine hippurate tablets market.
The increasing healthcare expenditure is expected to drive the growth of the methenamine hippurate tablets market. Healthcare expenditure refers to the total financial resources allocated for healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The rise in healthcare spending is primarily driven by the increasing prevalence of chronic diseases, which require long-term and often costly treatments. This increase in spending enhances the accessibility and availability of urinary antiseptic treatments like methenamine hippurate tablets for patients with recurrent urinary tract infections. Higher healthcare spending also supports better diagnostic services, more timely prescriptions, and improved treatment efficiency, ultimately leading to better patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, a 0.9% growth compared to 2022. As a result, the rising healthcare expenditure is contributing to the growth of the methenamine hippurate tablets market.
Major companies in the methenamine hippurate tablets market are forming strategic collaborations to enhance their profitability. Strategic collaboration involves a purposeful partnership between entities to achieve mutual goals by coordinating efforts and leveraging each other’s strengths and resources. For example, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical company that offers methenamine hippurate tablets, partnered with Dr. Pfleger Arzneimittel GmbH. Through this collaboration, EQL Pharma AB aims to launch Methenamine Hippurate under an EQL-registered brand within the next two years, with standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price contingent on regulatory approval. Dr. Pfleger Arzneimittel GmbH is a Germany-based pharmaceutical company.
Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.
North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methenamine hippurate tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the methenamine hippurate tablets market by increasing import costs for active pharmaceutical ingredients and packaging materials, which in turn raises production expenses. The hospital pharmacy and retail pharmacy segments, particularly in regions like Asia-Pacific and Africa that rely heavily on imports, are most impacted. Despite the challenges, tariffs have encouraged local manufacturing and sourcing strategies, potentially leading to cost optimization and reduced dependence on global supply chains, benefiting domestic market growth.
The methenamine hippurate tablets market research report is one of a series of new reports that provides methenamine hippurate tablets market statistics, including methenamine hippurate tablets industry global market size, regional shares, competitors with a methenamine hippurate tablets market share, detailed methenamine hippurate tablets market segments, market trends and opportunities, and any further data you may need to thrive in the methenamine hippurate tablets industry. This methenamine hippurate tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Methenamine Hippurate Tablets are an antimicrobial medication primarily used to prevent and treat urinary tract infections (UTIs). It works by creating an acidic environment in the urine, which inhibits bacterial growth. This medication is commonly prescribed for patients with recurrent UTIs to help reduce the frequency of infections.
The main types of methenamine hippurate tablets come in packs of 20 tablets or bottles and 6 tablets or bottles. These tablets are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. The primary applications include treating uncomplicated UTIs and healthcare-associated UTIs. The end-users of this medication include hospitals, home care settings, specialty clinics, and other healthcare providers.
The methenamine hippurate tablets market consists of sales of hexamine hippurate tablets, hiprex tablets, and urinary tract infection tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The methenamine hippurate tablets market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing incidence of urinary tract infections, growing demand for outpatient and homecare treatment, technological advancements in tablet formulation, rising adoption of personalized medicine, expansion of online pharmacy channels. Major trends in the forecast period include rising prevalence of recurrent utis, growth in geriatric population, increasing preference for oral antimicrobial therapies, expansion of home healthcare services, emergence of personalized medication regimens.
The rising incidence of urinary tract infections (UTIs) is expected to drive the growth of the methenamine hippurate tablets market. UTIs are common infections that occur when bacteria enter the urethra and infect the urinary tract, often originating from the skin or rectum. Methenamine hippurate tablets are used to prevent or treat recurrent UTIs caused by specific bacteria. For example, in October 2023, the National Health Service (NHS), a UK-based government department, reported that during the 2022-23 period, there were 147,285 hospital admissions for UTIs as the primary diagnosis. Of these, 56% (82,392) were individuals aged 65 and older, with the highest number of admissions occurring in the 80-84 age group, which accounted for 17,280 admissions. As a result, the rising number of UTI cases is contributing to the growth of the methenamine hippurate tablets market.
The increasing healthcare expenditure is expected to drive the growth of the methenamine hippurate tablets market. Healthcare expenditure refers to the total financial resources allocated for healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The rise in healthcare spending is primarily driven by the increasing prevalence of chronic diseases, which require long-term and often costly treatments. This increase in spending enhances the accessibility and availability of urinary antiseptic treatments like methenamine hippurate tablets for patients with recurrent urinary tract infections. Higher healthcare spending also supports better diagnostic services, more timely prescriptions, and improved treatment efficiency, ultimately leading to better patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, a 0.9% growth compared to 2022. As a result, the rising healthcare expenditure is contributing to the growth of the methenamine hippurate tablets market.
Major companies in the methenamine hippurate tablets market are forming strategic collaborations to enhance their profitability. Strategic collaboration involves a purposeful partnership between entities to achieve mutual goals by coordinating efforts and leveraging each other’s strengths and resources. For example, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical company that offers methenamine hippurate tablets, partnered with Dr. Pfleger Arzneimittel GmbH. Through this collaboration, EQL Pharma AB aims to launch Methenamine Hippurate under an EQL-registered brand within the next two years, with standard license fees, regulatory and reimbursement milestones, and a volume-dependent supply price contingent on regulatory approval. Dr. Pfleger Arzneimittel GmbH is a Germany-based pharmaceutical company.
Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.
North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methenamine hippurate tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the methenamine hippurate tablets market by increasing import costs for active pharmaceutical ingredients and packaging materials, which in turn raises production expenses. The hospital pharmacy and retail pharmacy segments, particularly in regions like Asia-Pacific and Africa that rely heavily on imports, are most impacted. Despite the challenges, tariffs have encouraged local manufacturing and sourcing strategies, potentially leading to cost optimization and reduced dependence on global supply chains, benefiting domestic market growth.
The methenamine hippurate tablets market research report is one of a series of new reports that provides methenamine hippurate tablets market statistics, including methenamine hippurate tablets industry global market size, regional shares, competitors with a methenamine hippurate tablets market share, detailed methenamine hippurate tablets market segments, market trends and opportunities, and any further data you may need to thrive in the methenamine hippurate tablets industry. This methenamine hippurate tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Methenamine Hippurate Tablets are an antimicrobial medication primarily used to prevent and treat urinary tract infections (UTIs). It works by creating an acidic environment in the urine, which inhibits bacterial growth. This medication is commonly prescribed for patients with recurrent UTIs to help reduce the frequency of infections.
The main types of methenamine hippurate tablets come in packs of 20 tablets or bottles and 6 tablets or bottles. These tablets are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. The primary applications include treating uncomplicated UTIs and healthcare-associated UTIs. The end-users of this medication include hospitals, home care settings, specialty clinics, and other healthcare providers.
The methenamine hippurate tablets market consists of sales of hexamine hippurate tablets, hiprex tablets, and urinary tract infection tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Methenamine Hippurate Tablets Market Characteristics
3. Methenamine Hippurate Tablets Market Supply Chain Analysis
4. Global Methenamine Hippurate Tablets Market Trends and Strategies
5. Methenamine Hippurate Tablets Market Analysis of End Use Industries
7. Global Methenamine Hippurate Tablets Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Methenamine Hippurate Tablets Total Addressable Market (TAM) Analysis for the Market
9. Methenamine Hippurate Tablets Market Segmentation
20 Tablets or Bottle, 6 Tablets or Bottle
10. Methenamine Hippurate Tablets Market Regional and Country Analysis
11. Asia-Pacific Methenamine Hippurate Tablets Market
12. China Methenamine Hippurate Tablets Market
13. India Methenamine Hippurate Tablets Market
14. Japan Methenamine Hippurate Tablets Market
15. Australia Methenamine Hippurate Tablets Market
16. Indonesia Methenamine Hippurate Tablets Market
17. South Korea Methenamine Hippurate Tablets Market
18. Taiwan Methenamine Hippurate Tablets Market
19. South East Asia Methenamine Hippurate Tablets Market
20. Western Europe Methenamine Hippurate Tablets Market
21. UK Methenamine Hippurate Tablets Market
22. Germany Methenamine Hippurate Tablets Market
23. France Methenamine Hippurate Tablets Market
24. Italy Methenamine Hippurate Tablets Market
25. Spain Methenamine Hippurate Tablets Market
26. Eastern Europe Methenamine Hippurate Tablets Market
27. Russia Methenamine Hippurate Tablets Market
28. North America Methenamine Hippurate Tablets Market
29. USA Methenamine Hippurate Tablets Market
30. Canada Methenamine Hippurate Tablets Market
31. South America Methenamine Hippurate Tablets Market
32. Brazil Methenamine Hippurate Tablets Market
33. Middle East Methenamine Hippurate Tablets Market
34. Africa Methenamine Hippurate Tablets Market
36. Methenamine Hippurate Tablets Market Competitive Landscape and Company Profiles
37. Methenamine Hippurate Tablets Market Other Major and Innovative Companies
40. Methenamine Hippurate Tablets Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Methenamine Hippurate Tablets Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses methenamine hippurate tablets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for methenamine hippurate tablets? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The methenamine hippurate tablets market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: 20 Tablets Or Bottle; 6 Tablets Or Bottle2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By Application: Uncomplicated UTIs; Healthcare-associated UTIs
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By 20 Tablets per Bottle: Standard Packaging; Bulk Packaging Options2) By 6 Tablets per Bottle: Standard Packaging; Sample Or Trial Packaging
Companies Mentioned: Alvogen Lux Holdings S.ÀR.L.; Micro Labs Inc.; Aurobindo Pharma; Amneal Pharmaceuticals Inc.; Viatris Inc.; Sun Pharmaceutical Industries Ltd.; Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Cadila Healthcare Ltd.; Torrent Pharmaceuticals Ltd.; Glenmark Pharmaceuticals Ltd.; Zydus Pharmaceuticals Ltd.; Lupin Ltd.; Alkem Laboratories Ltd.; Ipca Laboratories Ltd.; Granules India Ltd.; Teva Pharmaceutical Industries Ltd.; Apotex Pharmachem Inc.; Sandoz International GmbH; Mylan Laboratories Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Methenamine Hippurate Tablets market report include:- Alvogen Lux Holdings S.ÀR.L.
- Micro Labs Inc.
- Aurobindo Pharma
- Amneal Pharmaceuticals Inc.
- Viatris Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cadila Healthcare Ltd.
- Torrent Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd.
- Zydus Pharmaceuticals Ltd.
- Lupin Ltd.
- Alkem Laboratories Ltd.
- Ipca Laboratories Ltd.
- Granules India Ltd.
- Teva Pharmaceutical Industries Ltd.
- Apotex Pharmachem Inc.
- Sandoz International GmbH
- Mylan Laboratories Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.86 Billion |
| Forecasted Market Value ( USD | $ 14.49 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
